Gout Treatment and Clinical Considerations: The Role of Pegloticase, Colchicine, and Febuxostat

被引:3
|
作者
Quintana, Michael J. [1 ]
Shum, Alika Z. [1 ]
Folse, Michael S. [1 ]
Ramesh, Prerana C. [2 ]
Ahmadzadeh, Shahab [3 ]
Varrassi, Giustino [4 ]
Shekoohi, Sahar [3 ]
Kaye, Alan D. [3 ]
机构
[1] Louisiana State Univ, Hlth Sci Ctr, Sch Med, Shreveport, LA USA
[2] Louisiana State Univ, Hlth Sci Ctr, Radiol, Shreveport, LA USA
[3] Louisiana State Univ, Hlth Sci Ctr, Anesthesiol, Shreveport, LA 71103 USA
[4] Paolo Procacci Fdn, Pain Med, Rome, Italy
关键词
uric acid; gout; krystexxa (pegloticase); colcrys (colchicine); uloric (febuxostat); INDUCED HEMOLYTIC-ANEMIA; INHIBITOR; HYPERURICEMIA; SAFETY; PHARMACODYNAMICS; PHARMACOKINETICS; MULTICENTER; MANAGEMENT;
D O I
10.7759/cureus.46649
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Gout treatment has evolved rapidly in recent decades, and various drugs have been designed for acute and chronic management. Three medications used to treat gout include pegloticase, colchicine, and febuxostat. When prescribing these drugs, important factors to consider include pharmacokinetics, pharmacodynamics, population specifics, benefits, and contraindications. Pharmacokinetic considerations of each drug include absorption, distribution, metabolism, and elimination factors. Pharmacodynamics factors are assessed by their potential for toxicity and effects on serum uric acid levels. Additionally, the drug's targeted population must be considered to avoid unwanted complications in certain pre-existing conditions such as cardiovascular disease or glucose-6-dehydrogenase (G6PD) deficiency. In this paper, we aim to provide insight into the gout medications, pegloticase, colchicine, and febuxostat. This review will include their pharmacokinetics, pharmacodynamics, population specifics, benefits, and contraindications.
引用
收藏
页数:7
相关论文
共 50 条
  • [31] COLCHICINE ANALOGS IN THE TREATMENT OF ACUTE GOUT
    WALLACE, SL
    ARTHRITIS AND RHEUMATISM, 1959, 2 (05): : 389 - 395
  • [32] Febuxostat treatment for gout: what the clinician needs to know
    Chen, Lan X.
    Schumacher, H. Ralph
    THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE, 2009, 1 (02) : 67 - 69
  • [33] Febuxostat: the evidence for its use in the treatment of hyperuricemia and gout
    Gaffo, Angelo L.
    Saag, Kenneth G.
    CORE EVIDENCE, 2009, 4 : 25 - 36
  • [35] Complete Tophus Response in Patients with Chronic Gout Initiating Pegloticase Treatment
    Becker, Michael A.
    Gonter, Neil J.
    Pope, Janet E.
    Malamet, Raymond L.
    Baraf, Herbert S. B.
    ARTHRITIS AND RHEUMATISM, 2012, 64 (10): : S812 - S812
  • [36] Pegloticase Treatment Significantly Decreases Blood Pressure in Patients With Chronic Gout
    Johnson, Richard J.
    Choi, Hyon K.
    Yeo, Anthony E.
    Lipsky, Peter E.
    HYPERTENSION, 2019, 74 (01) : 95 - 101
  • [37] Patient considerations in the management of gout and role of combination treatment with lesinurad
    Claus, Liza W.
    Saseen, Joseph J.
    PATIENT-RELATED OUTCOME MEASURES, 2018, 9 : 231 - 238
  • [38] PHARMACOKINETICS OF PEGLOTICASE AND METHOTREXATE POLYGLUTAMATE(S) IN PATIENTS WITH UNCONTROLLED GOUT RECEIVING PEGLOTICASE AND CO-TREATMENT OF METHOTREXATE
    Song, Y.
    Xin, Y.
    Weinblatt, M. E.
    Chamberlain, J.
    Obermeyer, K.
    Zhao, L.
    Canavan, C.
    Peloso, P. M.
    Ramanathan, S.
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 847 - 848
  • [39] PHARMACOKINETICS OF PEGLOTICASE AND METHOTREXATE POLYGLUTAMATE(S) IN PATIENTS WITH UNCONTROLLED GOUT RECEIVING PEGLOTICASE AND CO-TREATMENT WITH METHOTREXATE
    Xin, Y.
    Song, Y.
    Weinblatt, M. E.
    Chamberlain, J.
    Zarzoso, J.
    Obermeyer, K.
    Sainati, S.
    Canavan, C.
    Ramanathan, S.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 910 - 910
  • [40] REAL-WORLD PATTERNS OF PEGLOTICASE USE FOR TREATMENT OF GOUT IN THE US
    Chen, S.
    Liu, J.
    Kim, S.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 1250 - 1250